2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Neoplasm Metastasis
5
Sarcoma
4
Neoplasms
4
Hematologic Neoplasms
4
Breast Neoplasms
4
Brain Neoplasms
4
Pancreatic Neoplasms
3
Melanoma
3
Glioma
3
Thyroid Cancer, Papillary
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Leukemia, Myeloid, Acute
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Uveal Melanoma
1
Thrombocytosis
1
Solid Tumors
1
Solid Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Rare Tumour
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Noonan Syndrome 6
1
Interventions
Vincristine
16
Cyclophosphamide
16
Filgrastim
13
Etoposide
12
Doxorubicin
12
Radiotherapy
11
Carboplatin
10
X-Rays
9
Dactinomycin
9
Specimen Handling
8
Phantoms, Imaging
8
Magnetic Resonance Spectroscopy
8
Granulocyte Colony-Stimulating Factor
8
Temozolomide
6
Melphalan
6
Ifosfamide
6
Topotecan
5
Polymerase Chain Reaction
5
Peripheral Blood Stem Cell Transplantation
5
Nuclear Medicine Department, Hospital
5
Irinotecan
5
Busulfan
5
Biopsy
5
sargramostim
4
Stem Cell Transplantation
4
Gene Expression Profiling
4
Amplified Fragment Length Polymorphism Analysis
4
Thiotepa
3
Reverse Transcriptase Polymerase Chain Reaction
3
Radiation
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Wilms Tumor
×
entrectinib
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA